Literature DB >> 24499875

The Ross procedure offers excellent survival compared with mechanical aortic valve replacement in a real-world setting.

Martin Andreas1, Dominik Wiedemann2, Gernot Seebacher2, Claus Rath2, Tandis Aref2, Raphael Rosenhek3, Georg Heinze4, Ernst Eigenbauer4, Paul Simon2, Kurt Ruetzler5, Joerg-Michael Hiesmayr5, Anton Moritz6, Guenther Laufer2, Alfred Kocher2.   

Abstract

OBJECTIVES: The ideal prosthesis for young patients requiring aortic valve replacement has not been defined to date. Although the Ross procedure provides excellent survival, its application is still limited. We compared the long-term survival after the Ross procedure with mechanical aortic valve replacement.
METHODS: All consecutive Ross procedures and mechanical aortic valve replacements performed between 1991 and 2008 at a single centre were analysed. Only adult patients between 18 and 50 years of age were included in the study. Survival and valve-related complications were evaluated. Furthermore, survival was compared with the age- and sex-matched Austrian population.
RESULTS: A total of 159 Ross patients and 173 mechanical valve patients were included. The cumulative survival for the Ross procedure was significantly better, with survival rates of 96, 94 and 93% at 5, 10 and 15 years, respectively, in comparison to 90, 84 and 75% (P < 0.01) for patients with mechanical valves. A Cox regression analysis including patients' age, gender and valve type revealed age and the type of aortic valve replacement as independent significant factors influencing survival (for age, hazard ratio = 1.1, 95% confidence interval = 1.0-1.1, P = 0.03; and for valve type, hazard ratio = 2.6, 95% confidence interval = 1.2-5.8, P = 0.02). The observed survival was comparable to the expected standard survival for the Ross group but was significantly reduced in the mechanical valve group.
CONCLUSIONS: In a real-world setting, the Ross procedure is associated with a long-term survival benefit in young adults in comparison to mechanical aortic valve replacement.
© The Author 2014. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Aortic valve replacement; Mechanical valve; Outcome (survival, reoperation); Pulmonary autograft; Ross operation

Mesh:

Year:  2014        PMID: 24499875     DOI: 10.1093/ejcts/ezt663

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  5 in total

1.  The Ross procedure: an excellent option in the right hands.

Authors:  Michael E Bowdish; S Ram Kumar; Vaughn A Starnes
Journal:  Ann Transl Med       Date:  2016-12

2.  Ross Procedure vs Mechanical Aortic Valve Replacement in Adults: A Systematic Review and Meta-analysis.

Authors:  Amine Mazine; Rodolfo V Rocha; Ismail El-Hamamsy; Maral Ouzounian; Bobby Yanagawa; Deepak L Bhatt; Subodh Verma; Jan O Friedrich
Journal:  JAMA Cardiol       Date:  2018-10-01       Impact factor: 14.676

3.  The Ross procedure: time for a hard look at current practices and a reexamination of the guidelines.

Authors:  Ismail El-Hamamsy; Ismail Bouhout
Journal:  Ann Transl Med       Date:  2017-03

4.  Conventional versus rapid-deployment aortic valve replacement: a single-centre comparison between the Edwards Magna valve and its rapid-deployment successor.

Authors:  Martin Andreas; Stephanie Wallner; Andreas Habertheuer; Claus Rath; Martin Schauperl; Thomas Binder; Dietrich Beitzke; Raphael Rosenhek; Christian Loewe; Dominik Wiedemann; Alfred Kocher; Guenther Laufer
Journal:  Interact Cardiovasc Thorac Surg       Date:  2016-03-13

5.  Decellularized aortic homografts for aortic valve and aorta ascendens replacement.

Authors:  Igor Tudorache; Alexander Horke; Serghei Cebotari; Samir Sarikouch; Dietmar Boethig; Thomas Breymann; Philipp Beerbaum; Harald Bertram; Mechthild Westhoff-Bleck; Karolina Theodoridis; Dmitry Bobylev; Eduard Cheptanaru; Anatol Ciubotaru; Axel Haverich
Journal:  Eur J Cardiothorac Surg       Date:  2016-02-18       Impact factor: 4.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.